Clinical Trial Update: A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating GLPG3970 for 12 weeks in adults with active primary Sjögren's syndrome was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• GLPG3970 (GLPG3970)

Snippet

Sponsor: Galapagos NV | Conditions: Primary Sjögren Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2023-09-18